SCHEMBL9963578

SCHEMBL9963578

Cc1c2nc(NCC(=O)NCCc3ccccn3)sc2cc2sc(NCC(=O)N3CCCCC3)nc12

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 3/20 0.44
PKM P14618 2/20 0.40
TAS1R3 Q7RTX0 1/20 0.40
TAS1R1 Q7RTX1 1/20 0.40
TSHR P16473 1/20 0.40
ALDH1A1 P00352 2/20 0.39
DPP4 P27487 1/20 0.39
KDM4E B2RXH2 1/20 0.38
EGLN1 Q9GZT9 3/20 0.38
F10 P00742 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
ADORA3 P0DMS8 1/20 0.37
ADORA2B P29275 1/20 0.37
MAPT P10636 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
CHRM4 P08173 1/20 0.37
HTT P42858 1/20 0.36
RAB9A P51151 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9963623 0.87 ADORA2B (0.47) PTGS2ALDH1A1KDM4ESMN1; SMN2ADORA3
SCHEMBL9963646 0.84 ALDH1A1 (0.48) PTGS2TSHRALDH1A1KDM4EADORA3
SCHEMBL9963651 0.84 PTGS2 (0.44) PTGS2TSHRALDH1A1KDM4EMAPT
SCHEMBL9963534 0.83 BCHE (0.40) PTGS2TAS1R3TAS1R1ALDH1A1KDM4E
SCHEMBL9963636 0.82 PTGS2 (0.46) PTGS2TSHRALDH1A1SMN1; SMN2MAPT
SCHEMBL9963634 0.82 PTGS2 (0.42) PTGS2TSHRALDH1A1KDM4ESMN1; SMN2
SCHEMBL9963581 0.82 PTGS2 (0.42) PTGS2TSHRALDH1A1KDM4EMAPT
SCHEMBL9963628 0.79 PTGS2 (0.41) PTGS2TSHRALDH1A1KDM4ERAB9A
SCHEMBL9963545 0.78 PTGS2 (0.51) PTGS2TSHRALDH1A1SMN1; SMN2MAPT
SCHEMBL9963596 0.77 LCK (0.42) PTGS2ALDH1A1MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2032583-B1 NEW CHEMICAL COMPOUNDS BOEHRINGER INGELHEIM INT (DE) 2014-11-19 EP disclosed
US-8203001-B2 Chemical compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-06-19 US disclosed
US-8203001-B2 Chemical compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-06-19 US disclosed
US-20090258857-A1 CHEMICAL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-10-15 US disclosed
US-20090258857-A1 CHEMICAL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-10-15 US disclosed
WO-2007144370-A1 NEW CHEMICAL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090258857-A1 CHEMICAL COMPOUNDS CCNA1, CCNT1, MKI67 PTGS2 2872/4885PKM 1131/4885TAS1R3 2917/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.